157 related articles for article (PubMed ID: 33141285)
1. The role of dendritic cells for therapy of B-cell lymphoma with immune checkpoint inhibitors.
Scheuerpflug A; Ahmetlić F; Bauer V; Riedel T; Röcken M; Mocikat R
Cancer Immunol Immunother; 2021 May; 70(5):1343-1350. PubMed ID: 33141285
[TBL] [Abstract][Full Text] [Related]
2. CD40-independent natural killer-cell help promotes dendritic cell vaccine-induced T-cell immunity against endogenous B-cell lymphoma.
Hömberg N; Adam C; Riedel T; Brenner C; Flatley A; Röcken M; Mocikat R
Int J Cancer; 2014 Dec; 135(12):2825-33. PubMed ID: 24771135
[TBL] [Abstract][Full Text] [Related]
3. Alterations of costimulatory molecules and instructive cytokines expressed by dendritic cells in the microenvironment of an endogenous mouse lymphoma.
Naujoks M; Weiß J; Riedel T; Hömberg N; Przewoznik M; Noessner E; Röcken M; Mocikat R
Cancer Immunol Immunother; 2014 May; 63(5):491-9. PubMed ID: 24638151
[TBL] [Abstract][Full Text] [Related]
4. Therapy of lymphoma by immune checkpoint inhibitors: the role of T cells, NK cells and cytokine-induced tumor senescence.
Ahmetlic F; Fauser J; Riedel T; Bauer V; Flessner C; Hömberg N; Hennel R; Brenner E; Lauber K; Röcken M; Mocikat R
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33441389
[TBL] [Abstract][Full Text] [Related]
5. Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity.
Morrison AH; Diamond MS; Hay CA; Byrne KT; Vonderheide RH
Proc Natl Acad Sci U S A; 2020 Apr; 117(14):8022-8031. PubMed ID: 32213589
[TBL] [Abstract][Full Text] [Related]
6. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
da Cunha A; Antoniazi Michelin M; Cândido Murta EF
Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
[TBL] [Abstract][Full Text] [Related]
7. Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12.
Garris CS; Arlauckas SP; Kohler RH; Trefny MP; Garren S; Piot C; Engblom C; Pfirschke C; Siwicki M; Gungabeesoon J; Freeman GJ; Warren SE; Ong S; Browning E; Twitty CG; Pierce RH; Le MH; Algazi AP; Daud AI; Pai SI; Zippelius A; Weissleder R; Pittet MJ
Immunity; 2018 Dec; 49(6):1148-1161.e7. PubMed ID: 30552023
[TBL] [Abstract][Full Text] [Related]
8. Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy.
Schetters STT; Rodriguez E; Kruijssen LJW; Crommentuijn MHW; Boon L; Van den Bossche J; Den Haan JMM; Van Kooyk Y
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690667
[TBL] [Abstract][Full Text] [Related]
9. Dendritic cells combined with tumor cells and α-galactosylceramide induce a potent, therapeutic and NK-cell dependent antitumor immunity in B cell lymphoma.
Escribà-Garcia L; Alvarez-Fernández C; Tellez-Gabriel M; Sierra J; Briones J
J Transl Med; 2017 May; 15(1):115. PubMed ID: 28549432
[TBL] [Abstract][Full Text] [Related]
10. Enhanced anti-tumor effects of the PD-1 blockade combined with a highly absorptive form of curcumin targeting STAT3.
Hayakawa T; Yaguchi T; Kawakami Y
Cancer Sci; 2020 Dec; 111(12):4326-4335. PubMed ID: 33006786
[TBL] [Abstract][Full Text] [Related]
11. Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade.
Huffaker TB; Lee SH; Tang WW; Wallace JA; Alexander M; Runtsch MC; Larsen DK; Thompson J; Ramstead AG; Voth WP; Hu R; Round JL; Williams MA; O'Connell RM
J Biol Chem; 2017 Nov; 292(45):18530-18541. PubMed ID: 28912267
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-10 counteracts T-helper type 1 responses in B-cell lymphoma and is a target for tumor immunotherapy.
Ma Y; Bauer V; Riedel T; Ahmetlić F; Hömberg N; Hofer TP; Röcken M; Mocikat R
Cancer Lett; 2021 Apr; 503():110-116. PubMed ID: 33524501
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes.
Sun NY; Chen YL; Lin HW; Chiang YC; Chang CF; Tai YJ; Chen CA; Sun WZ; Chien CL; Cheng WF
Cancer Lett; 2019 Mar; 444():20-34. PubMed ID: 30543813
[TBL] [Abstract][Full Text] [Related]
14. Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4
Beavis PA; Henderson MA; Giuffrida L; Davenport AJ; Petley EV; House IG; Lai J; Sek K; Milenkovski N; John LB; Mardiana S; Slaney CY; Trapani JA; Loi S; Kershaw MH; Haynes NM; Darcy PK
Cancer Immunol Res; 2018 Sep; 6(9):1069-1081. PubMed ID: 30018045
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint blockade impairs immunosuppressive mechanisms of regulatory T cells in B-cell lymphoma.
Bauer V; Ahmetlić F; Hömberg N; Geishauser A; Röcken M; Mocikat R
Transl Oncol; 2021 Sep; 14(9):101170. PubMed ID: 34229208
[TBL] [Abstract][Full Text] [Related]
16. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer therapy using immune checkpoint molecules to target recombinant dendritic cells.
Choi SY; Kim Y; Lim B; Wee CB; Chang IH; Kim CS
Investig Clin Urol; 2024 May; 65(3):300-310. PubMed ID: 38714521
[TBL] [Abstract][Full Text] [Related]
18. Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.
Han X; Li H; Zhou D; Chen Z; Gu Z
Acc Chem Res; 2020 Nov; 53(11):2521-2533. PubMed ID: 33073988
[TBL] [Abstract][Full Text] [Related]
19. Targeting immune checkpoints in hematological malignancies.
Salik B; Smyth MJ; Nakamura K
J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses.
Kumar A; Ramani V; Bharti V; de Lima Bellan D; Saleh N; Uzhachenko R; Shen C; Arteaga C; Richmond A; Reddy SM; Vilgelm A
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37230537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
